Most Popular
![[KH Explains] No more 'Michael' at Kakao Games](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/28/20240428050183_0.jpg&u=20240428180321)
![[Grace Kao] Hybe vs. Ador: Inspiration, imitation and plagiarism](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/28/20240428050220_0.jpg&u=)
-
6
[Herald Interview] Mom’s Touch seeks to replicate success in Japan
![[Herald Interview] Mom’s Touch seeks to replicate success in Japan](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/29/20240429050568_0.jpg&u=)
-
7
Police to open alleged stalking probe over pastor over Dior bag scandal
-
8
'Queen of Tears' finale sets record viewership ratings as tvN's most-watched series ending
-
9
[News Focus] Lee tells Yoon that he has governed without political dialogue
![[News Focus] Lee tells Yoon that he has governed without political dialogue](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/29/20240429050696_0.jpg&u=20240429210658)
-
10
KT launches new mobile plans for foreign residents
![[Herald Interview] Mom’s Touch seeks to replicate success in Japan](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/29/20240429050568_0.jpg&u=)
![[News Focus] Lee tells Yoon that he has governed without political dialogue](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/29/20240429050696_0.jpg&u=20240429210658)
Medytox CEO to meet Allergan to discuss start of phase 3 trials of Innotox
By Sohn Ji-youngPublished : July 11, 2017 - 16:11
Medytox CEO Jung Hyun-ho is slated to meet with executives at Allergan to discuss the start of phase 3 clinical trials of its liquid-type botulinum toxin Innotox this week, according to local news reports Tuesday.
Medytox and Allergan struck a license partnership in 2013, when the Seoul-based company sold the global development and commercialization rights to Innotox to Allergan for $360 million.
Jung’s recent visit to the US is aimed at cementing a concrete timetable for the US clinical trials of Innotox, according to local reports.
Medytox and Allergan struck a license partnership in 2013, when the Seoul-based company sold the global development and commercialization rights to Innotox to Allergan for $360 million.
Jung’s recent visit to the US is aimed at cementing a concrete timetable for the US clinical trials of Innotox, according to local reports.
Allergan announced in its 2016 second quarter earnings report that it would begin the third-phase trials of Innotox in early 2017. However it is yet to begin the trials due to scale-up production issues with Medytox. Since then, Allergan had not publicized further plans for Innotox, fueling investor concerns.
A Medytox official told a local news outlet that the given production issues have been resolved and that it “expects Allergan to begin the phase 3 trials of Innotox by the end of this year.”
If Allergan does decide to carry out the final-stage trials of Innotox, the move is expected to lend a major revenue boost to Medytox which will produce and sell the liquid-injectable antiwrinkle fillers to be used in the trials to its global partner.
A Medytox spokesperson could not be reached for comment when contacted by The Korea Herald on Tuesday.
By Sohn Ji-young (jys@heraldcorp.com)
![[Today’s K-pop] Seventeen sets sales record with best-of album](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=642&simg=/content/image/2024/04/30/20240430050818_0.jpg&u=)